[Brief] WSJ: Hype for Moderna's Cancer Vaccine Runs Ahead of the Math
The Wall Street Journal analysis notes that market expectations for Moderna and Merck’s cancer vaccine mRNA-4157 may exceed what the data supports. While the vaccine showed promise in reducing recurrence risk in melanoma trials, sample sizes remain limited and long-term efficacy is unverified. Analysts caution that mRNA technology applications in oncology are still in early stages, and investors should be wary of short-term price volatility. Editor: GoodInfo Global News Team ...